Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin microneedle array - SkinJect

Next Previous
Drug Profile

Doxorubicin microneedle array - SkinJect

Alternative Names: D-MNA; Doxorubicin-containing MNA - SkinJect; SkinJect™

Latest Information Update: 05 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkinJect
  • Class Alcohols; Amines; Anisoles; Anthracyclines; Antineoplastics; Benzoquinones; Catechols; Cyclic ethers; Cyclohexanols; Cytostatic antibiotics; Doxorubicins; Ketones; Naphthacenes; Pyrans; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Basal cell cancer

Most Recent Events

  • 27 Jul 2026 USFDA issued study may proceed letter for phase IIb SKNJCT-005 trial in Basal cell nevus syndrome and other Basal cell cancer
  • 15 Jun 2026 Medicus Pharma submits Rare Pediatric Disease Designation application to the US FDA for Basal cell nevus syndrome
  • 03 Jun 2026 Medicus Pharma announces intention to submit Rare Pediatric Disease Priority Review Voucher to the US FDA for Basal cell nevus syndrome before the end of the second quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top